HCV genotype 4, 5 and 6: Distribution of viral subtypes and sustained virologic response rates in clinical trials of approved direct-acting antiviral regimens

Journal of Viral Hepatitis

Volumn 25, Issue 8, 2018, Pages 969-975

  Boyd, S D ^a   Harrington, P ^a   Komatsu, T E ^a   Naeger, L K ^a   Chan Tack, K ^a   Murray, J ^a   Birnkrant, D ^a   Struble, K ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

direct acting antiviral; genotype 4, 5, 6; hepatitis C virus; subtype; sustained virologic response

Indexed keywords

ELBASVIR PLUS GRAZOPREVIR; GLECAPREVIR PLUS PIBRENTASVIR; LEDIPASVIR PLUS SOFOSBUVIR; OMBITASVIR PLUS PARITAPREVIR PLUS RITONAVIR; RIBAVIRIN; SOFOSBUVIR PLUS VELPATASVIR; SOFOSBUVIR PLUS VELPATASVIR PLUS VOXILAPREVIR; ANTIVIRUS AGENT;

ANTIVIRAL THERAPY; ARTICLE; DRUG APPROVAL; GENERAL PRACTITIONER; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS GENOTYPE 4; HEPATITIS C VIRUS GENOTYPE 5; HEPATITIS C VIRUS GENOTYPE 6; HUMAN; MAJOR CLINICAL STUDY; NONHUMAN; PRIORITY JOURNAL; SUSTAINED VIROLOGIC RESPONSE; TREATMENT DURATION; TREATMENT OUTCOME; CHRONIC HEPATITIS C; CLASSIFICATION; CLINICAL TRIAL (TOPIC); GENETICS; HEPACIVIRUS; ISOLATION AND PURIFICATION; UNITED STATES; VIROLOGY;

ANTIVIRAL AGENTS; CLINICAL TRIALS AS TOPIC; GENOTYPE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; SUSTAINED VIROLOGIC RESPONSE; TREATMENT OUTCOME; UNITED STATES;

EID: 85050811161     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12896     Document Type: Article

References (49)

1. Dibonaventura MD, Yuan Y, Lescrauwaet B, et al. Multicountry burden of chronic hepatitis C viral infection among those aware of their diagnosis: a patient survey. PLoS ONE. 2014;9:e86070.
2. Fattovich G, Giustina G, Degos F, et al. Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients. Gastroenterology. 1997;112:463-472.
3. Planas R, Balleste B, Alvarez MA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. J Hepatol. 2004;40:823-830.
4. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61(1 Suppl):S45-S57.
5. Backus LI, Boothroyd DB, Phillips BR, Belperio P, Halloran J, Mole LA. A sustained virologic response reduces risk of all-cause mortality in patients with hepatitis C. Clin Gastroenterol Hepatol. 2011;9:509-516, e501.
6. van der Meer AJ, Veldt BJ, Feld JJ, et al. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584-2593.
7. Messina JP, Humphreys I, Flaxman A, et al. Global distribution and prevalence of hepatitis C virus genotypes. Hepatology. 2015;61:77-87.
8. Smith DB, Bukh J, Kuiken C, et al. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318-327.
9. International Committee on Taxonomy of Viruses. Confirmed HCV genotypes/subtypes (June 2017). https://talk.ictvonline.org/ictv_wikis/flaviviridae/w/sg_flavi/634/table-1_confirmed-hcv-genotypes-subtypes Accessed September 20, 2017.
10. Asante-Appiah E, Curry S, McMonagle P, et al. Antiviral activity and resistance analysis of NS3/4A protease inhibitor grazoprevir and NS5A inhibitor elbasvir in hepatitis C virus GT4 replicons. Antimicrob Agents Chemother. 2017;61:e00363-17.
11. Komatsu T, Harrington P, O'Rear J. FDA Clinical Virology Review and Evaluation. NDA 208261. Zepatier (elbasvir/grazoprevir). 2016. https://www.accessdata.fda.gov/scripts/cder/daf/
12. Cheng G, Tian Y, Doehle B, et al. In vitro antiviral activity and resistance profile characterization of the hepatitis C virus NS5A inhibitor ledipasvir. Antimicrob Agents Chemother. 2016;60:1847-1853.
13. Ng TI, Tripathi R, Reisch T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS3/4A protease inhibitor glecaprevir. Antimicrob Agents Chemother. 2018;62:e01620-17.
14. Pilot-Matias T, Tripathi R, Cohen D, et al. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988-997.
15. Ng TI, Krishnan P, Pilot-Matias T, et al. In vitro antiviral activity and resistance profile of the next-generation hepatitis C virus NS5A inhibitor pibrentasvir. Antimicrob Agents Chemother. 2017;61:e02558–16.
16. Krishnan P, Beyer J, Mistry N, et al. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979-987.
17. Donaldson E, O'Rear J. FDA Clinical Virology Review and Evaluation. NDA 208341. Epclusa (sofosbuvir/velpatasvir). 2016. https://www.accessdata.fda.gov/scripts/cder/daf/
18. Naeger L, O'Rear J. FDA Clinical Virology Review and Evaluation. NDA 209195. Vosevi (sofosbuvir/velpatasvir/voxilaprevir). 2017. https://www.accessdata.fda.gov/scripts/cder/daf/
19. Harrington P, O'Rear J. FDA Clinical Virology Review and Evaluation. NDA 209394. Mavyret (glecaprevir/pibrentasvir). 2017. https://www.accessdata.fda.gov/scripts/cder/daf/
20. Fleischer R, Harrington P, Qi X, O'Rear J, Smith F, Murray J. FDA Medical Review and Evaluation. NDA 207931. Technivie (ombitasvir/paritaprevir/ritonavir). 2015. https://www.accessdata.fda.gov/scripts/cder/daf/
21. Camus G, Han B, Asselah T, et al. Resistance characterization of ledipasvir and velpatasvir in hepatitis C virus genotype 4. J Viral Hepat. 2018;25:134-143.
22. Zeuzem S, Ghalib R, Reddy KR, et al. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1-13.
23. Rockstroh JK, Nelson M, Katlama C, et al. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319-e327.
24. Boyd S, Viswanathan P, Sherwat A. FDA Medical Review and Evaluation. NDA 208261. Zepatier (elbasvir/grazoprevir). 2016. https://www.accessdata.fda.gov/scripts/cder/daf/
25. Gane EJ, Lawitz E, Pugatch D, et al. EXPEDITION-IV: safety and efficacy of GLE/PIB in adults with renal impairment and chronic hepatitis C virus genotype 1–6 Infection. Hepatology. 2016;64:1125A.
26. Forns X, Lee SS, Valdes J, et al. Glecaprevir plus pibrentasvir for chronic hepatitis C virus genotype 1, 2, 4, 5, or 6 infection in adults with compensated cirrhosis (EXPEDITION-1): a single-arm, open-label, multicentre phase 3 trial. Lancet Infect Dis. 2017;17:1062-1068.
27. Asselah T, Kowdley KV, Zadeikis N, et al. Efficacy of glecaprevir/pibrentasvir for 8 or 12 weeks in patients with hepatitis C virus genotype 2, 4, 5, or 6 infection without cirrhosis. Clin Gastroenterol Hepatol. 2018;16:417-426.
28. Abergel A, Asselah T, Metivier S, et al. Ledipasvir-sofosbuvir in patients with hepatitis C virus genotype 5 infection: an open-label, multicentre, single-arm, phase 2 study. Lancet Infect Dis. 2016;16:459-464.
29. Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64:1049-1056.
30. Naggie S, Cooper C, Saag M, et al. Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1. N Engl J Med. 2015;373:705-713.
31. Charlton M, Everson GT, Flamm SL, et al. Ledipasvir and sofosbuvir plus ribavirin for treatment of HCV infection in patients with advanced liver disease. Gastroenterology. 2015;149:649-659.
32. Manns M, Samuel D, Gane EJ, et al. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685-697.
33. Gane EJ, Hyland RH, An D, et al. Efficacy of ledipasvir and sofosbuvir, with or without ribavirin, for 12 weeks in patients with HCV genotype 3 or 6 infection. Gastroenterology. 2015;149:1454-1461, e1451.
34. Asselah T, Hezode C, Qaqish RB, et al. Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial. Lancet Gastroenterol Hepatol. 2016;1:25-35.
35. Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385:2502-2509.
36. Curry MP, O'Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618-2628.
37. Feld JJ, Jacobson IM, Hezode C, et al. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599-2607.
38. Bourliere M, Gordon SC, Flamm SL, et al. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134-2146.
39. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER). Chronic Hepatitis C Virus Infection: Developing Direct-Acting Antiviral Drugs for Treatment, Guidance for Industry. November 2017. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-drugs-gen/documents/document/ucm225333.pdf Accessed November 8, 2017.
40. Welzel TM, Bhardwaj N, Hedskog C, et al. Global epidemiology of HCV subtypes and resistance-associated substitutions evaluated by sequencing-based subtype analyses. J Hepatol. 2017;67:224-236.
41. FDA Clinical Virology Review and Evaluation. NDA 205834 S2-S6. Harvoni (ledipasvir/sofosbuvir). 2015.
42. Kamal SM, Nasser IA. Hepatitis C genotype 4: what we know and what we don't yet know. Hepatology. 2008;47:1371-1383.
43. Ruane PJ, Ain D, Stryker R, et al. Sofosbuvir plus ribavirin for the treatment of chronic genotype 4 hepatitis C virus infection in patients of Egyptian ancestry. J Hepatol. 2015;62:1040-1046.
44. HARVONI® (ledipasvir and sofosbuvir) tablets, [package insert]. Foster City, CA: Gilead Pharmaceuticals, Inc. 2014 (approved). http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/205834s010lbl.pdf. Accessed September 20, 2017.
45. TECHNIVIE® (ombitasvir, paritaprevir and ritonavir) tablets, [package insert]. North Chicago, IL: AbbVie, Inc. 2015 (approved). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/207931s007s009lbl.pdf. Accessed September 20, 2017.
46. ZEPATIER® (elbasvir and grazoprevir) tablets, [package insert]. Whitehouse Station, NJ: Merck & CO, Inc. 2016 (approved). http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208261Orig1s000lbl.pdf. Accessed 20 September, 2017.
47. EPCLUSA® (sofosbuvir and velpatasvir) tablets, [package insert]. Foster City, CA: Gilead Pharmaceuticals, Inc. 2016 (approved). http://www.accessdata.fda.gov/drugsatfda_docs/label/2016/208341s000lbl.pdf. Accessed September 20, 2017.
48. VOSEVI® (sofosbuvir, velpatasvir, and voxilaprevir) tablets, [package insert]. Foster City, CA: Gilead Pharmaceuticals, Inc. 2017 (approved). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209195s000lbl.pdf. Accessed September 20, 2017.
49. MAVYRET® (glecaprevir and pibrentasvir tablets), [package insert]. North Chicago, IL: AbbVie, Inc. 2017 (approved). https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209394s000lbl.pdf. Accessed 20 September 2017.